Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258647 | 1.00 | AKR1C1 (0.40) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5262258 | 0.91 | NNMT (0.35) | PDE10AFGFR4ADORA2AKMT2AHCAR3 | |
| SCHEMBL5262263 | 0.91 | NNMT (0.35) | PDE10AFGFR4ADORA2AKMT2AHCAR3 | |
| SCHEMBL5263036 | 0.89 | ADORA2A (0.38) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5263038 | 0.89 | ADORA2A (0.38) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5260968 | 0.88 | ADORA2A (0.48) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5260969 | 0.88 | ADORA2A (0.48) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5261682 | 0.87 | ADORA2A (0.39) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5261678 | 0.87 | ADORA2A (0.39) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 | |
| SCHEMBL5261350 | 0.87 | BRD4 (0.38) | AKR1C1AKR1C2AKR1C3PDE10AFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | claimed |
| EP-1309590-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-05-14 | — | — | EP | claimed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | claimed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| WO-2001098299-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | disclosed |
| US-6486322-B1 | Azaindole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-11-26 | — | — | US | disclosed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | FFAR4, AZI2, CNKSR1 | AKR1C1 915/4885AKR1C2 930/4885AKR1C3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.